Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ORA
|
|||
| Former ID |
DIB013996
|
|||
| Drug Name |
MOR-103
|
|||
| Synonyms |
MOR-04357; Antibody (inflammation), MorphoSys; GM-CSF antibody (rheumatoid arthritis), MorphoSys; MOR-103 (rheumatoid arthritis), MorphoSys; GM-CSF antibody (iv infusion, inflammation), MorphoSys/Galapagos
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 1/2 | [1] | |
| Company |
Glaxosmithkline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GMCSFR-alpha (CSF2RA) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| NetPath Pathway | IL3 Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Pathway Interaction Database | GMCSF-mediated signaling events | |||
| Alpha9 beta1 integrin signaling events | ||||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| RAF/MAP kinase cascade | ||||
| Surfactant metabolism | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | Interleukin-2 signaling | |||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01023256) Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
| REF 2 | MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.